Cas:23434-88-0 Tetrahydropiperine manufacturer & supplier

Chemical Name:Tetrahydropiperine

CAS.NO:23434-88-0

Synonyms:1-[5-(1,3-Benzodioxol-5-yl)pentanoyl]piperidine;Tetrahydropiperidine;5-(1,3-Benzodioxol-5-yl)-1-(piperidin-1-yl)pentan-1-one;Tetrahydropiperin;1-Pentanone, 5-(1,3-benzodioxol-5-yl)-1-(1-piperidinyl)-;5-(1,3-Benzodioxol-5-yl)-1-(1-piperidinyl)-1-pentanone;Piperidine, 1-[5-(1,3-benzodioxol-5-yl)-1-oxopentyl]-;Cosmoperine;Tetrahydropiperine

Molecular Formula:C₁₇H₂₃NO₃

Molecular Weight:289.369

HS Code:

Physical and Chemical Properties:

Melting point:41ºC

Boiling point:469.9±24.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.556

PSA:38.77000

Exact Mass:289.167786

LogP:3.67

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-[5-(1,3-Benzodioxol-5-yl)pentanoyl]piperidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tetrahydropiperine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Piperidine, 1-[5-(1,3-benzodioxol-5-yl)-1-oxopentyl]- Use and application,Tetrahydropiperine technical grade,usp/ep/jp grade.

Related News: Delta said it will suspend flights between the United States and China starting on Sunday until at least April 30, according to a press release. Tetrahydropiperine manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. Tetrahydropiperine supplier The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. Tetrahydropiperine vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. Tetrahydropiperine factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.